MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. `Innovations in Regenerative Biomaterials` is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant.
| Revenue (Most Recent Fiscal Year) | $348.88M |
| Net Income (Most Recent Fiscal Year) | $42.42M |
| PE Ratio (Current Year Earnings Estimate) | 23.23 |
| PE Ratio (Trailing 12 Months) | 21.57 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.53 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.40 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 18.23 |
| Pre-Tax Margin (Trailing 12 Months) | 15.47% |
| Net Margin (Trailing 12 Months) | 11.40% |
| Return on Equity (Trailing 12 Months) | 22.70% |
| Return on Assets (Trailing 12 Months) | 16.77% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.70 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.13 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.09 |
| Inventory Turnover (Trailing 12 Months) | 2.62 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.31 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.06 |
| Earnings per Share (Most Recent Fiscal Year) | $0.29 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.27 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 147.70M |
| Free Float | 145.19M |
| Market Capitalization | $892.12M |
| Average Volume (Last 20 Days) | 0.52M |
| Beta (Past 60 Months) | 1.83 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 79.15% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |